aprott/iStock via Getty Images A new survey has found that employer coverage of GLP-1 drugs for both diabetes and obesity has increased significantly over the past six months. According to a survey by the International Foundation of Employee Benefit Plans, the percentage of US employers providing coverage of GLP-1s for diabetes has risen to 57% from 49% in its October survey, while coverage of the drugs for both diabetes and weight loss has climbed to 34% from 26%. The survey also found that 19% of employers who cover GLP-1s for diabetes only are also considering covering them for weight loss.
Respondents indicated that on average, GLP-1 drugs represented 8.9% of their total annual claims, up from 6.9% in the October survey.
The organization added that 85% of employers who cover the drugs “rely heavily on utilization management to control costs,” including prior authorization and BMI and/or comorbidity requirements, according to the survey . The survey, conducted in late May 2024, included responses from 279 employers. The two leading makers of GLP-1 drugs for the US market are Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ).
More on Eli Lilly, Novartis, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? Employer coverage for GLP-1s rising amid FDA label expansions: survey Lilly's Retevmo gains traditional approval in t.
